Table 3.

Adverse events.

Variable	TACE + RT + Sorafenib (n = 28)			TACE + RT (n = 35)			P-value
	Grade 1 (%)	Grade 2 (%)	Grade 3 (%)	Grade 1 (%)	Grade 2 (%)	Grade 3 (%)
Hematological	20 (71.4)		4 (14.3)	26 (74.3)		6 (17.1)	0.620
Leukopenia	9 (32.1)	12 (42.9)	0 (0)	13 (37.1)	8 (22.9)	6 (17.1)	0.087
Anemia	5 (17.9)	0 (0)	0 (0)	7 (20.0)	0 (0)	1 (2.9)	0.559
Thrombocytopenia	9 (32.1)	9 (32.1)	4 (14.3)	9 (25.7)	10 (28.6)	5 (14.3)	0.758
Hepatotoxicity	25 (89.3)		3 (10.7)	23 (65.7)		4 (11.4)	0.705
Increased ALT level	5 (17.9)	0 (0)	0 (0)	8 (22.9)	1 (2.9)	0 (0)	0.532
Increased AST level	19 (67.9)	0 (0)	0 (0)	17 (48.6)	1 (2.9)	1 (2.9)	0.742
Increased ALP level	7 (25.0)	0 (0)	0 (0)	9 (25.7)	0 (0)	0 (0)	1.000
Increased bilirubin level	18 (64.3)	0 (0)	0 (0)	20 (57.1)	2 (5.7)	0 (0)	0.754
Hypoproteinemia	7 (25.0)	0 (0)	0 (0)	5 (14.3)	0 (0)	0 (0)	0.343
Increased GGT level	17 (60.7)	5 (17.9)	3 (10.7)	15 (42.9)	7 (20.0)	3 (8.6)	0.365
Dermatological
Hand-foot syndrome	4 (14.3)	1 (3.6)	0 (0)	0 (0)	0 (0)	0 (0)	0.013
Other skin reactions	25 (89.3)	1 (3.6)	0 (0)	24 (68.6)	0 (0)	0 (0)	0.011
Gastrointestinal
Nausea	4 (14.3)	0 (0)	0 (0)	2 (5.7)	1 (2.9)	0 (0)	0.767
Vomit	1 (3.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0.444
Anorexia	6 (21.4)	0 (0)	0 (0)	5 (14.3)	0 (0)	0 (0)	0.517
Diarrhea	8 (28.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0.001
Other
Fatigue	6 (21.4)	1 (10.7)	0 (0)	7 (20.0)	1 (2.9)	0 (0)	0.256
Hair loss	4 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0.034

ALP, Alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; IMRT, intensity-modulated radiotherapy; TACE, transcatheter arterial chemoembolization.